UBS downgraded Fresenius Medical (FMS) to Sell from Neutral with a price target of EUR 38, down from EUR 43.50. The firm says its new analysis shows the company’s U.S. dialysis volumes face long-term funnel and mortality challenges. It believes Fresenius Medical’s volume misses will be structural.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 46 from EUR 43 at Morgan Stanley
- Fresenius Medical Care Launches EUR 1 Billion Share Buyback Program
- Fresenius Medical announces first tranche of share buyback program
- Fresenius Medical price target lowered to EUR 48 from EUR 50 at Deutsche Bank
- Hold Rating Maintained for Fresenius Medical Care Amidst Flat US Growth and Downward Financial Adjustments